Format

Send to

Choose Destination
Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15936. [Epub ahead of print]

Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.

Author information

1
Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
2
Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
3
Department of Radiotherapy, Leiden University Medical Centre, Leiden, the Netherlands.
4
Department of Radiotherapy, Radboud University Medical Centre, Nijmegen, the Netherlands.
5
Department of Radiotherapy, Erasmus Medical Centre, Rotterdam, the Netherlands.
6
Department of Haematology, University Medical Centre Utrecht, Utrecht, the Netherlands.
7
Department of Haematology, Amsterdam UMC, Location VU Medical Centre, Amsterdam, the Netherlands.
8
Department of Haematology, University Medical Centre Groningen, Groningen, the Netherlands.
9
Department of Radiotherapy, MAASTRO Clinic, Maastricht, the Netherlands.
10
Department of Haematology, Reinier de Graaf Group, Delft, the Netherlands.
11
Department of Haematology, Isala, Zwolle, the Netherlands.
12
Department of Radiotherapy, Zeeuws Radiotherapy Institute, Vlissingen, the Netherlands.
13
Department of Haematology, Adrz Hospital, Goes, the Netherlands.
14
Department of Haematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
15
Department of Haematology, Amphia Hospital, Breda, the Netherlands.
16
Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.

KEYWORDS:

Hodgkin lymphoma; long-term adverse effects; screening guidelines; survivorship care

PMID:
31090916
DOI:
10.1111/bjh.15936

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center